Cart
0

Vaccines Market by Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease; Influenza, Human Papilloma Virus; Meningococcal Disease; Rotavirus; Varicella; Diphtheria, Pertussis, & Tetanus {DTP}, Polio, Hepatitis, Measles, Mumps, & Rubella {MMR}, and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_17258
Pages: 240
May 2017 | 2779 Views
 
Author's : Garima Chandra
Tables: 90
Charts: 68
 

Vaccines Market Overview:

Global Vaccines Market was valued at $31,216 million in 2016, and is expected to reach $65,148 million in 2023, and register a CAGR of 10.9%, during the forecast period, 2017‐ 2023. Vaccine is a biological preparation that is administered to produce acquired immunity in patients. Administration of vaccines aids to enhance the immune response against a specific pathogen.

Vaccinations play a crucial role to maintain sustainable health of people across different countries; hence, they are employed in various regional disease-prevention strategies. The demand for vaccinations has increased over the last few years, owing to the increase in incidence of both viral and bacterial infectious diseases. Vaccinations are essentially administered to people of different age groups, which strengthens their immune system throughout lifetime and offers protection against different types of infectious diseases.

The global vaccines market is driven by the rise in prevalence of infectious diseases, as it is considered to be the best way to prevent such diseases. In addition, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), production of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs supplement the market growth. However, longer timelines required to produce vaccines and high monetary inputs associated with the same restrict the market growth. Furthermore, high growth of vaccine production in emerging markets is expected to offer lucrative opportunities in the near future.

Global Vaccines Market Segmentation

Global Vaccines Market Segmentation

Get more information on this report : Request Sample Pages

Segment Review

The vaccines market is segmented based on technology, indication, end use, and region. Based on technology, it is classified into conjugate vaccines, inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, and other vaccines. Based on indication, it is divided into influenza; pneumococcal disease; meningococcal disease; human papilloma virus; rotavirus; varicella; diphtheria, pertussis, and tetanus (DTP), polio; hepatitis; measles, mumps, and rubella (MMR); and other indications. Based on end use, it is divided into pediatric vaccines, adult vaccines, and traveler vaccines.

Global Vaccines Market By End Use

Global vaccines market by end use

Get more information on this report : Request Sample Pages

Adult vaccines possess high market potential for growth of vaccines, owing to increase in incidence of human papilloma virus infections in adults. However, the pediatric vaccines segment dominates the market, owing to the high demand for vaccines in infants, such as BCG vaccines, MMR vaccines, and DPT vaccines. In addition, traveler vaccines offer significant opportunities for expansion of vaccines market.

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new markets and increase in adoption of combination vaccines in prevention strategies by government provide new growth opportunities in the near future.

Drivers, Restraints, and Opportunities

Drivers, restraints, and opportunities

Get more information on this report : Request Sample Pages

The report provides a comprehensive analysis of the key players operating in the global vaccines market, such as Astellas Pharma Inc., Astrazeneca Plc. (Medimmune, LLC.), CSL Limited, Emergent Biosolutions, Inc., Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur, and Serum Institute of India Pvt. Ltd.

The other key players in the value chain include Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Prokarium, and ImmunoBiology Ltd.

Key Market Benefits of the Vaccines Market Report:

  • It provides an in-depth analysis of current trends and future estimations to elucidate the imminent investment pockets
  • It offers a comprehensive analysis of factors that drive and restrict the market growth
  • It presents a quantitative analysis of the industry to enable the stakeholders to capitalize on the prevailing market opportunities
  • It provides an extensive analysis of key segments to understand the type of products and indications used globally
  • It includes profiles of key market players and their strategies to comprehend the competitive outlook of the market.

Vaccines Market Key Segments:

By Technology

  • Conjugate Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Other Vaccines

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella
  • Diphtheria, Pertussis, and Tetanus (DPT)
  • Polio
  • Hepatitis
  • Measles, Mumps, and Rubella (MMR)
  • Other Indications

By End Use

  • Pediatric Vaccines
  • Adult Vaccines
  • Traveler Vaccines

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Turkey
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. GOVERNMENT REGULATIONS

3.4.1. FDA
3.4.2. CE Mark
3.4.3. Therapeutic Goods Administration (TGA)
3.4.4. Ministry of Health, Labour and Welfare (MHLW)

3.5. MARKET SHARE ANALYSIS, 2016
3.6. VACCINE PRODUCT AND PIPELINE ANALYSIS
3.7. CLINICAL TRIALS BY KEY PLAYERS
3.8. MARKET DYNAMICS

3.8.1. Drivers

3.8.1.1. High prevalence of diseases
3.8.1.2. Increase in government focus on immunization programs
3.8.1.3. Emerging vaccines
3.8.1.4. Technological progress in vaccine administration

3.8.2. Restraints

3.8.2.1. Longer timelines required for vaccine production
3.8.2.2. High costs associated with the development of vaccines

3.8.3. Opportunity

3.8.3.1. High growth prospects in emerging markets

Chapter: 4 VACCINES MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CONJUGATE VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. INACTIVATED VACCINES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. LIVE ATTENUATED VACCINES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. TOXOID VACCINES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. RECOMBINANT VACCINES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHER VACCINES

4.7.1. Market size and forecast

Chapter: 5 VACCINES MARKET, BY END USE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PEDIATRIC VACCINES

5.2.1. Market size and forecast

5.3. ADULT VACCINES

5.3.1. Market size and forecast

5.4. TRAVELER VACCINES

5.4.1. Market size and forecast

Chapter: 6 VACCINES MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. PNEUMOCOCCAL DISEASE

6.2.1. Market size and forecast

6.3. INFLUENZA

6.3.1. Market size and forecast

6.4. HUMAN PAPILLOMA VIRUS

6.4.1. Market size and forecast

6.5. MENINGOCOCCAL DISEASE

6.5.1. Market size and forecast

6.6. ROTAVIRUS

6.6.1. Market size and forecast

6.7. VARICELLA

6.7.1. Market size and forecast

6.8. DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT)

6.8.1. Market size and forecast

6.9. POLIO

6.9.1. Market size and forecast

6.10. HEPATITIS

6.10.1. Market size and forecast

6.11. MEASLES, MUMPS, AND RUBELLA (MMR)

6.11.1. Market size and forecast

6.12. OTHER INDICATIONS

6.12.1. Market size and forecast

Chapter: 7 VACCINES MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. UK market size and forecast
7.3.5. France market size and forecast
7.3.6. Germany market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Australia market size and forecast
7.4.8. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil market size and forecast
7.5.5. Argentina market size and forecast
7.5.6. Turkey market size and forecast
7.5.7. South Africa market size and forecast
7.5.8. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ASTELLAS PHARMA INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Product portfolio
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. ASTRAZENECA PLC (MEDIMMUNE, LLC)

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. CSL LIMITED

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. EMERGENT BIOSOLUTIONS, INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GLAXOSMITHKLINE PLC

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. JOHNSON & JOHNSON

8.6.1. Company overview
8.6.2. Company Snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. MERCK & CO., INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. PFIZER INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. SANOFI

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SERUM INSTITUTE OF INDIA PVT. LTD.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Key strategic moves and developments

LIST OF TABLES

TABLE 1. SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT
TABLE 2. LOT-RELEASE TESTING GUIDELINES
TABLE 3. TOP FIVE BEST SELLING VACCINE PRODUCTS, 2015 & 2022
TABLE 4. TOP FIVE R&D VACCINE PRODUCTS UNDER PIPELINE, 2015 & 2022
TABLE 5. GLOBAL VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 6. CONJUGATE VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. LIST OF COMMERCIAL INACTIVATED VACCINES
TABLE 8. INACTIVATED VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. LIST OF COMMERCIAL LIVE ATTENUATED VACCINES
TABLE 10. LIVE ATTENUATED VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. TOXOID VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. LIST OF COMMERCIAL RECOMBINANT VACCINES
TABLE 13. RECOMBINANT VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. OTHER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 16. PEDIATRIC VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. RECOMMENDED IMMUNIZATION SCHEDULE, U.S., 2017
TABLE 18. ADULT VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. TRAVELER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 21. COMPANY PRODUCT ANALYSIS OF PNEUMOCOCCAL VACCINES IN U.S.
TABLE 22. VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2016-2023 ($MILLION)
TABLE 23. INFLUENZA VACCINE RECOMMENDATIONS BY CDC, 2016-2017
TABLE 24. COMPANY PRODUCT ANALYSIS OF INFLUENZA VACCINES IN U.S.
TABLE 25. VACCINES MARKET FOR INFLUENZA, BY REGION, 2016-2023 ($MILLION)
TABLE 26. HUMAN PAPILLOMA VIRUS RECOMMENDATIONS BY CDC, 2016-2017
TABLE 27. COMPANY PRODUCT ANALYSIS OF HUMAN PAPILLOMA VACCINES IN U.S.
TABLE 28. VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2016-2023 ($MILLION)
TABLE 29. COMPANY PRODUCT ANALYSIS OF MENINGOCOCCAL VACCINES IN U.S.
TABLE 30. MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. COMPANY PRODUCT ANALYSIS OF ROTAVIRUS VACCINES IN U.S.
TABLE 32. ROTAVIRUS VACCINE RECOMMENDATIONS BY CDC, 2016-2017
TABLE 33. VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2016-2023 ($MILLION)
TABLE 34. COMPANY PRODUCT ANALYSIS OF VARICELLA VACCINES IN U.S.
TABLE 35. VACCINES MARKET FOR VARICELLA, BY REGION, 2016-2023 ($MILLION)
TABLE 36. COMPANY PRODUCT ANALYSIS OF DPT VACCINES IN U.S.
TABLE 37. VACCINES MARKET FOR DPT, BY REGION, 2016-2023 ($MILLION)
TABLE 38. COMPANY PRODUCT ANALYSIS OF POLIO VACCINES IN U.S.
TABLE 39. VACCINES MARKET FOR POLIO, BY REGION, 2016-2023 ($MILLION)
TABLE 40. COMPANY PRODUCT ANALYSIS OF HEPATITIS VACCINES IN U.S.
TABLE 41. VACCINES MARKET FOR HEPATITIS, BY REGION, 2016-2023 ($MILLION)
TABLE 42. COMPANY PRODUCT ANALYSIS OF MMR VACCINES IN U.S.
TABLE 43. VACCINES MARKET FOR MMR, BY REGION, 2016-2023 ($MILLION)
TABLE 44. COMPANY PRODUCT ANALYSIS OF OTHER VACCINES IN U.S.
TABLE 45. VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 46. VACCINES MARKET, BY REGION ($MILLION)
TABLE 47. NORTH AMERICA VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 48. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 49. NORTH AMERICA VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 50. NORTH AMERICA VACCINES MARKET, BY END USE ($MILLION)
TABLE 51. EUROPE VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 52. EUROPE VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 53. EUROPE VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 54. EUROPE VACCINES MARKET, BY END USE ($MILLION)
TABLE 55. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 56. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 57. ASIA-PACIFIC VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 58. ASIA-PACIFIC VACCINES MARKET, BY END USE ($MILLION)
TABLE 59. LAMEA VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 60. LAMEA VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 61. LAMEA VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 62. LAMEA VACCINES MARKET, BY END USE ($MILLION)
TABLE 63. ASTELLAS: COMPANY SNAPSHOT
TABLE 64. ASTELLAS: PRODUCT PORTFOLIO
TABLE 65. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 66. ASTRAZENECA: OPERATING SEGMENTS
TABLE 67. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 68. CSL: COMPANY SNAPSHOT
TABLE 69. CSL: OPERATING SEGMENTS
TABLE 70. CSL: PRODUCT PORTFOLIO
TABLE 71. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 72. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 73. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 74. GSK: COMPANY SNAPSHOT
TABLE 75. GSK: OPERATING SEGMENTS
TABLE 76. GSK: PRODUCT PORTFOLIO
TABLE 77. J&J: COMPANY SNAPSHOT
TABLE 78. J&J: OPERATING SEGMENTS
TABLE 79. J&J: PRODUCT PORTFOLIO
TABLE 80. MERCK: COMPANY SNAPSHOT
TABLE 81. MERCK: OPERATING SEGMENTS
TABLE 82. MERCK: PRODUCT PORTFOLIO
TABLE 83. PFIZER: COMPANY SNAPSHOT
TABLE 84. PFIZER: OPERATING SEGMENTS
TABLE 85. PFIZER: PRODUCT PORTFOLIO
TABLE 86. SANOFI: COMPANY SNAPSHOT
TABLE 87. SANOFI: OPERATING SEGMENTS
TABLE 88. SANOFI: PRODUCT PORTFOLIO
TABLE 89. SERUM INSTITUTE OF INDIA: COMPANY SNAPSHOT
TABLE 90. SERUM INSTITUTE OF INDIA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. SNAPSHOT OF GLOBAL VACCINES MARKET, 2017-2023
FIGURE 2. SNAPSHOT OF GLOBAL VACCINES, BY REGION
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES, 2014-2017 (%)
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 7. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 8. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 9. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 10. BARGAINING POWER OF BUYERS
FIGURE 11. BARGAINING POWER OF SUPPLIERS
FIGURE 12. THREAT OF NEW ENTRANTS
FIGURE 13. THREAT OF SUBSTITUTION
FIGURE 14. COMPETITIVE RIVALRY
FIGURE 15. FDA REGULATION ANALYSIS
FIGURE 16. VACCINE APPROVAL PROCESS
FIGURE 17. MARKET SHARE ANALYSIS, 2016
FIGURE 18. CLINICAL TRIALS FOR VACCINES MARKET BY TOP PLAYERS (%)
FIGURE 19. VACCINE CLINICAL TRIAL DEVELOPMENT FOR DIFFERENT INDICATION
FIGURE 20. RESTRAINTS AND DRIVERS
FIGURE 21. VACCINE DEVELOPMENT CYCLE
FIGURE 22. GLOBAL VACCINES MARKET: TECHNOLOGY SEGMENTATION
FIGURE 23. STATISTICAL ANALYSIS OF APPLICATION OF CONJUGATE VACCINES IN THE PREVENTION OF DISEASES
FIGURE 24. GLOBAL VACCINES MARKET: END USE SHARE ANALYSIS, 2016
FIGURE 25. TYPES OF TRAVEL VACCINES IN UK
FIGURE 26. PNEUMOCOCCAL DISEASES AMONG CHILDREN AGED <5 YEARS IN U.S.
FIGURE 27. U.S. VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 28. CANADA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 29. MEXICO VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 30. UK VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 31. FRANCE VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 32. GERMANY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 33. ITALY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 34. SPAIN VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 35. REST OF EUROPE VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 36. JAPAN VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 37. CHINA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 38. INDIA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 39. AUSTRALIA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 40. REST OF ASIA PACIFIC VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 41. BRAZIL VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 42. ARGENTINA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 43. TURKEY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 44. SOUTH AFRICA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 45. REST OF LAMEA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 46. ASTELLAS: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 48. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 49. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. CSL: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. CSL: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 52. CSL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. EMERGENT: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 55. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 56. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 57. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 58. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 59. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 60. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 61. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 62. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 63. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 64. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 65. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 66. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 67. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 68. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

The vaccines market is expected to register a significant growth, owing to the increase in vaccination against different infectious diseases. The market has gained momentum due to the introduction of novel recombinant vaccines in the prevention of infectious diseases. In addition, conjugate vaccines incorporated in the prevention of both bacterial (Neisseria meningitides) and viral infectious (H. influenza) diseases supplement the market growth.

Vaccines are essentially administered to offer protection against diseases, such as pneumococcal diseases, influenza, meningococcal diseases, and others. However, vaccines have been largely employed in the prevention of pneumococcal diseases over the past few years. Escalating incidences of cervical cancer in women, affecting approximately 500, 000 women annually in 80% of the developing countries, has increased the demand for vaccines against human papilloma virus.

Vaccine development is a time-consuming process requiring approximately 11-12 years for production before its commercial use. In addition, high financial investment in the manufacturing process of vaccines restrains the growth of the market. However, emerging markets, such as Asia-Pacific and Africa, have taken initiatives to focus on immunization programs, which offer lucrative opportunities for the market growth. Introduction of novel vaccines, such as herpes zoster vaccine (GlaxoSmithKline), respiratory syncytial virus (RSV) vaccine (Novavax), and staphylococcus aureus vaccine (Pfizer) in the Phase III clinical trials, offer significant potential for market growth. The demand for vaccines administered in adults is expected to grow considerably in the near future, owing to the increase in incidence of influenza and human papilloma virus in both males and females. Furthermore, vaccines are essential for the travelers susceptible to infectious diseases when traveling to different regions, which contributes to the growing demand for vaccines in people among different age groups.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Vaccines Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo